Results 31 to 40 of about 15,615 (185)

Programmable three‐state nanoreactor for spatiotemporally controlled tumor therapy

BMEMat, EarlyView.
The OMVs are shielded with a biocompatible Da–Ca shell, which prolongs its circulation period and promotes intratumoral accumulation. Importantly, the biocompatible Da–Ca shell can be controllably disintegrated in tumor microenvironment by using laser irradiation, generating in situ hyperthermia and releasing Ca2+.
Guihong Lu, Peng Ye, Xiaoyan Li, Ke Ma, Chengliang Lyu, Kai Zhang, Ran Luo, Yang Ji, Shiqi Mei, Fan Zhang, Jinxie Zhang, Lin Mei, Hui Tan   +12 more
wiley   +1 more source

Evaluation of Chlorogenic Acid in Parkinson’s Disease Model: An In-vitro Study in 6-OHDA Induced SH-SY5Y Cell Line [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Parkinson’s Disease (PD) is the most common neurodegenerative movement disorder. Mitochondrial dysfunction is a key pathological driver of PD.
Sunprakathi Alwarsamy Perumalsamy, Kranthi Karunai Kadal, Gowri Viswanathan, Kavitha Ramasamy   +3 more
doaj   +1 more source

High-frequency stimulation of the subthalamic nucleus counteracts cortical expression of major histocompatibility complex genes in a rat model of Parkinson's disease. [PDF]

PLoS ONE, 2014
High-frequency stimulation of the subthalamic nucleus (STN-HFS) is widely used as therapeutic intervention in patients suffering from advanced Parkinson's disease.
Benjamin Grieb, Gerhard Engler, Andrew Sharott, Constantin von Nicolai, Thomas Streichert, Ismini Papageorgiou, Alexander Schulte, Manfred Westphal, Katrin Lamszus, Andreas K Engel, Christian K E Moll, Wolfgang Hamel   +11 more
doaj   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Investigation of the antioxidant activity of hesperidin against 6-hydroxydopamine-induced cell damage in SH-SY5Y cells

National Journal of Physiology, Pharmacy and Pharmacology, 2018
Background: Parkinson’s disease (PD) is regarded as a neurological condition in which continuous degeneration of dopaminergic neurons occurs selectively. Currently, most treatments for neurodegenerative diseases are palliative.
Mehrdad Jahanshahi, Leila Elyasi, Hamed Ghazvini, Emsehgol Nikmahzar, Shohreh Taziki   +4 more
doaj   +1 more source

Cordycepin mediates neuroprotection against apoptosis via ERK/CREB signaling activation in Aβ1–42‐induced neuronal cell models

Ibrain, Volume 11, Issue 1, Page 84-97, Spring 2025.
This study demonstrates cordycepin's neuroprotective effects against Aβ1–42‐induced apoptosis in neuronal cells, mediated through the activation of the extracellular signal‐regulated kinase/cyclic AMP‐responsive element‐binding protein (ERK/CREB) signaling pathway.
Wenshu Zhou, Cheng Wang, Yige Tan, Philip Lazarovici, Xiaoyan Wen, Shaoping Li, Wenhua Zheng   +6 more
wiley   +1 more source

Effects of 6-Hydroxydopamine on the Canine Sinus Node [PDF]

Circulation Research, 1971
The acute effects of 6-hydroxydopamine (6-OH-DA) injected directly into the sinus node artery were studied in 57 dogs. The positive chronotropic effect of 6-OH-DA was intermediate between that of norepinephrine and that of tyramine, when these substances were compared on the basis of their ED 50 .
V, Elharrar, J, de Champlain, R A, Nadeau   +2 more
openaire   +2 more sources

Neuroprotective effect of quercetin in a model of Parkinson’s disease in rat: A histochemical analysis

Basic and Clinical Neuroscience, 2009
Introduction: Parkinson's disease (PD) is a neuropathological disorder involving the degeneration of dopaminergic neurons in the substantia nigra, with the subsequent loss of their terminals in the striatum.
Mehdi Mehdizadeh, Mohammad Taghi Joghataei, Maliheh Nobakht, Roya Aryanpour   +3 more
doaj   +2 more sources

Neuroprotective effects of quercetin in animal models of neurodegenerative diseases: A systematic review and meta‐analysis

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease are characterized by progressive neuronal loss driven by oxidative stress and inflammation. Quercetin, a dietary flavonoid with established antioxidant and anti‐inflammatory properties, has emerged as a potential neuroprotective agent.
In Ho Cho, Hendra Mahakam Putra, Cheol Woon Jung, Gyu Hwan Hyun, Hwan‐Hee Jang, In Guk Hwang, Sung Won Kwon   +6 more
wiley   +1 more source

Apathy in Lewy Body Disorders: A Position Paper

Movement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky, Lidia Bojtos, Milica G. Kramberger, Elisa Mantovani, Iulia Murasan, Jose‐Alberto Palma, Karolina Poplawska‐Domaszewicz, Anna Sauerbier, Kallol Ray Chaudhuri, Per Odin, Daniel Weintraub, Anette Schrag, Cristian Falup‐Pecorariu   +12 more
wiley   +1 more source